Intensified Treatments for Patients With Locally Advanced Nasopharyngeal Carcinoma With Detectable EBV DNA After One Cycle GP Regime Neoadjuvant Chemotherapy

The goal of this multicenter randomized non-inferior study is to compare the additon of camrelizumab or nimotuzumab to neoadjuvant chemotherapy followed by concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma patients whose EBV DNA remained detectable after one cycle neoadjuvant chemotherapy using GP regimen. The main question it aims to answer is: whether the addition of carrilizumab or nituzumab improve the treatment outcomes in the relatively poor prognostic patients identified by the response of EBV DNA. Participants will be randomized to the combination of carrilizuma

Trial Details

NCT ID
NCT05772208
Phase
PHASE3
Sponsor
Fudan University
Status
RECRUITING
Cancer Type
Head and Neck Cancer
Interventions
  • Camrelizumab
  • Nimotuzumab
  • neoadjuvant chemotherapy and CCRT
Locations (sample)
  • Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

  • Patients with newly histologically confirmed non-keratinizing nasopharyngeal carcinoma, type of WHO II or III, EGFR+.
  • Age 18-70 years.
  • Clinical stage III-IVa (based on the 8th American Joint Committee on Cancer\[AJCC\] edition).
  • Patients with detectable pre-treatment plasma EBV DNA which remained detectable after one cycle neoadjuvant.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Head and Neck Cancer Trials on Trialify →